These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1379 related items for PubMed ID: 9628768

  • 21. Cross-sensitization between caffeine- and L-dopa-induced behaviors in hemiparkinsonian mice.
    Yu L, Schwarzschild MA, Chen JF.
    Neurosci Lett; 2006 Jan 23; 393(1):31-5. PubMed ID: 16236444
    [Abstract] [Full Text] [Related]

  • 22. Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease.
    Lundblad M, Andersson M, Winkler C, Kirik D, Wierup N, Cenci MA.
    Eur J Neurosci; 2002 Jan 23; 15(1):120-32. PubMed ID: 11860512
    [Abstract] [Full Text] [Related]

  • 23. A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function.
    Lundblad M, Picconi B, Lindgren H, Cenci MA.
    Neurobiol Dis; 2004 Jun 23; 16(1):110-23. PubMed ID: 15207268
    [Abstract] [Full Text] [Related]

  • 24. The selective alpha1 adrenoceptor antagonist HEAT reduces L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
    Buck K, Ferger B.
    Synapse; 2010 Feb 23; 64(2):117-26. PubMed ID: 19771592
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Bilateral subthalamic nucleus lesion reverses L-dopa-induced motor fluctuations and facilitates dyskinetic movements in hemiparkinsonian rats.
    Marin C, Jiménez A, Tolosa E, Bonastre M, Bové J.
    Synapse; 2004 Feb 23; 51(2):140-50. PubMed ID: 14618681
    [Abstract] [Full Text] [Related]

  • 27. The alpha(2) adrenoceptor antagonist idazoxan alleviates L-DOPA-induced dyskinesia by reduction of striatal dopamine levels: an in vivo microdialysis study in 6-hydroxydopamine-lesioned rats.
    Buck K, Voehringer P, Ferger B.
    J Neurochem; 2010 Jan 23; 112(2):444-52. PubMed ID: 19895663
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease.
    Savola JM, Hill M, Engstrom M, Merivuori H, Wurster S, McGuire SG, Fox SH, Crossman AR, Brotchie JM.
    Mov Disord; 2003 Aug 23; 18(8):872-83. PubMed ID: 12889076
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease.
    Visanji NP, Fox SH, Johnston T, Reyes G, Millan MJ, Brotchie JM.
    Neurobiol Dis; 2009 Aug 23; 35(2):184-92. PubMed ID: 19118628
    [Abstract] [Full Text] [Related]

  • 34. Effect of non-dopaminergic drug treatment on Levodopa induced dyskinesias in MPTP monkeys: common implication of striatal neuropeptides.
    Tamim MK, Samadi P, Morissette M, Grégoire L, Ouattara B, Lévesque D, Rouillard C, Di Paolo T.
    Neuropharmacology; 2010 Jan 23; 58(1):286-96. PubMed ID: 19576910
    [Abstract] [Full Text] [Related]

  • 35. Comparison of intrastriatal administration of noradrenaline and l-DOPA on dyskinetic movements: a bilateral reverse in vivo microdialysis study in 6-hydroxydopamine-lesioned rats.
    Buck K, Ferger B.
    Neuroscience; 2009 Mar 03; 159(1):16-20. PubMed ID: 19146929
    [Abstract] [Full Text] [Related]

  • 36. Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease.
    Dekundy A, Pietraszek M, Schaefer D, Cenci MA, Danysz W.
    Brain Res Bull; 2006 Apr 14; 69(3):318-26. PubMed ID: 16564428
    [Abstract] [Full Text] [Related]

  • 37. Upregulation of striatal adenosine A2A receptor mRNA in 6-hydroxydopamine-lesioned rats intermittently treated with L-DOPA.
    Tomiyama M, Kimura T, Maeda T, Tanaka H, Kannari K, Baba M.
    Synapse; 2004 Jun 01; 52(3):218-22. PubMed ID: 15065221
    [Abstract] [Full Text] [Related]

  • 38. Motor stimulant effects of the adenosine A2A receptor antagonist SCH 58261 do not develop tolerance after repeated treatments in 6-hydroxydopamine-lesioned rats.
    Pinna A, Fenu S, Morelli M.
    Synapse; 2001 Mar 01; 39(3):233-8. PubMed ID: 11284438
    [Abstract] [Full Text] [Related]

  • 39. Enhancement of the behavioral response to apomorphine administration following repeated treatment in the 6-hydroxydopamine-lesioned rat is temporally correlated with a rise in striatal preproenkephalin-B, but not preproenkephalin-A, gene expression.
    Duty S, Brotchie JM.
    Exp Neurol; 1997 Apr 01; 144(2):423-32. PubMed ID: 9168843
    [Abstract] [Full Text] [Related]

  • 40. ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice.
    Pavón N, Martín AB, Mendialdua A, Moratalla R.
    Biol Psychiatry; 2006 Jan 01; 59(1):64-74. PubMed ID: 16139809
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 69.